WAVE Life Sciences (NASDAQ:WVE) Stock, Quote.Headers.trade-ideas

WAVE Life Sciences

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Gene Sequencing

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

General

BEAM

KRRO

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1 antitrypsin deficiency.

Gene Editing Korro Bio&#39;s Preclinical Data &#39;Best-In-Class&#39;, Analyst Initiates With Outperform Rating

Image 4

Pre-Market Outlook

Markets

Trading Ideas

APTV

Larimar Therapeutics, Inc. - Common Stock

LRMR

TSHA

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

Wave Life Sciences reports Phase 1b/2a SELECT-HD trial results for WVE-003 in Huntington&#39;s disease, demonstrates promise as a disease-modifying therapy.

What&#39;s Going On With Wave Life Sciences Stock On Tuesday?

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences Ltd

WIIM

Wave Life Sciences shares are trading higher after B. Riley Securities initiated coverage on the stock with a Buy rating and announced a price target of $11.

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

Price Target

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Wave Life Sciences shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $10 price target.

JP Morgan initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight rating and announces Price Target of $10.

JP Morgan Initiates Coverage On WAVE Life Sciences with Overweight Rating, Announces Price Target of $10

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>), a private RNA editing company that went public via a reverse merger with&nbsp;Frequency Therapeutics Inc. in an all-stock&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33229914/why-are-frequency-therapeutics-shares-surging-today" rel="noreferrer noopener">merger transaction</a>.&nbsp;
The company&#8217;s proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform harnesses the body&#8217;s natural base editing system – specifically ADAR (Adenosine&nbsp;Deaminase&nbsp;Acting on&nbsp;RNA) – to make targeted edits to a single RNA base.
William Blair notes that ADAR editing permits chronic dosing and titratability of a genetic editing medicine without the risk of permanent off-target effects or potential issues with over- or underexpression of target genes.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36075434/why-newly-listed-korro-bio-shares-are-gaining-today" rel="noreferrer noopener">Why Newly Listed Korro Bio Shares Are Gaining Today?</a>
William Blair emphasizes that Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is set to release the first clinical data for an ADAR-recruiting therapy in 2024. The analyst initiates <a target="_blank" href="https://www.benzinga.com/quote/KRRO/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>.
The data from the Phase 1b/2a RestorAATion-2 trial of WVE-006 for severe Alpha-1 antitrypsin deficiency (A1ATD) will be crucial in determining whether the ADAR-mediated RNA editing mechanism is consistent across species—a key concern for investors due to differences in genetic homology.
Korro&#8217;s lead asset, KRRO-110, is a lipid nanoparticle (LNP)- encapsulated oligonucleotide designed to correct the E342K PiZ mutation in SERPINA1, which can lead to severe forms of alpha-1 antitrypsin deficiency (A1ATD).
The asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024, with interim proof-of-concept clinical data in 2025 and trial completion in 2026.
&#8220;We believe Korro&#8217;s preclinical data package, particularly in the NSG PiZ mouse model, is best-in-class for the ADAR field,&#8221; William Blair analyst writes.
&#8220;We also believe that Wave&#8217;s WVE-006 (GalNAc-conjugated ADAR-recruiting ASO) and Beam Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) BEAM-302 (base editing approach) clinical programs validate Korro&#8217;s approach but still leave clear room for differentiation on efficacy or specificity/safety,&#8221; the analyst adds.
Price Action: KRRO stock is up 8.64% at $39.50 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40373358/acelyrin-cuts-workforce-deprioritizes-former-lead-drug-izokibep" target="_blank" rel="noreferrer noopener">Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a> on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
Image via Shutterstock

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

Wave Life Sciences shares are trading higher after the company announced that the FDA has granted Rare Pediatric Disease Designation to WVE-N531 for the treatment of Duchenne muscular dystrophy.

Wave Life Sciences Announces FDA Has Granted Rare Pediatric Disease Designation To WVE-N531 For Treatment Of Duchenne Muscular Dystrophy

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated WAVE Life Sciences and provided 12-month price targets. The average target is $14.25, accompanied by a high estimate of $19.00 and a low estimate of $11.00. A decline of 16.18% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1723219254_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of WAVE Life Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Novack</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$11.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to WAVE Life Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for WAVE Life Sciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into WAVE Life Sciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know WAVE Life Sciences Better</h2>
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>Key Indicators: WAVE Life Sciences's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining WAVE Life Sciences's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -3.02% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -251.7%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): WAVE Life Sciences's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -97.07%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): WAVE Life Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.37%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.2, WAVE Life Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)

Jones Trading analyst Catherine Novack initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $12.

Jones Trading Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $12

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 25 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $19.692 million which missed the analyst consensus estimate of $24.335 million by 19.08 percent. This is a 10.92 percent decrease over sales of $22.106 million the same period last year.

Earnings

Earnings Misses

WAVE Life Sciences Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $19.692M Miss $24.335M Estimate

During the last three months, 4 analysts shared their evaluations of WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.5, a high estimate of $19.00, and a low estimate of $11.00. Observing a downward trend, the current average is 8.82% lower than the prior average price target of $17.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1719421240_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of WAVE Life Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WAVE Life Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of WAVE Life Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind WAVE Life Sciences</h2>
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>WAVE Life Sciences: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: WAVE Life Sciences's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -3.02%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: WAVE Life Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -251.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -97.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): WAVE Life Sciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.37%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: WAVE Life Sciences's debt-to-equity ratio is below the industry average. With a ratio of 1.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About WAVE Life Sciences Stock

HC Wainwright &amp; Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and maintains $15 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $15 Price Target

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday.
Shares of Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) fell sharply in today's pre-market trading after the company posted downbeat <a href="https://www.benzinga.com/quote/WOR/earnings">quarterly results</a>.
Worthington Industries posted adjusted earnings of 74 cents per share, missing analysts' estimates of 94 cents per share. The company posted quarterly sales of $318.801 million versus estimates of $359.390 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Worthington shares dipped 7.5% to $46.38 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares tumbled 14% to $2.12 in pre-market trading after the company reported a proposed public offering of common stock and pre-funded warrants.</li>
<li>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) fell 6.6% to $68.49 in pre-market trading. Piper Sandler analyst Alexander Potter downgraded Aptiv from Neutral to Underweight and lowered the price target from $78 to $63.</li>
<li>Qudian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QD#NYSE">QD</a>) shares fell 5.9% to $1.90 in pre-market trading.</li>
<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares declined 5.8% to $4.49 in pre-market trading after falling over 8% on Tuesday. The company announced results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003.</li>
<li>General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) shares slipped 4.5% to $64.24 in pre-market trading following fourth-quarter results.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) shares fell 3.8% to $6.77 in pre-market trading. JP Morgan analyst Ranjan Sharma downgraded Sea from Overweight to Neutral and lowered the price target from $84 to $78.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 3.7% to $35.00 in pre-market trading after gaining over 8% on Tuesday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39478022/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Wave Life Sciences are trading lower. The company announced results from its Phase 1b/2a SELECT-HD clinical trial of WVE-003.

Mizuho analyst Salim Syed reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and maintains $19 price target.

Mizuho Reiterates Outperform on WAVE Life Sciences, Maintains $19 Price Target

Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) announced results from its Phase 1b/2a SELECT-HD trial of WVE-003, which is being developed as a potential disease-modifying therapeutic for <a href="https://www.benzinga.com/pressreleases/24/06/g39474955/wave-life-sciences-announces-positive-results-from-phase-1b2a-select-hd-trial-with-first-clinical-">Huntington&#8217;s disease (HD)</a>.
WVE-003 is designed to lower mutant huntingtin (mHTT) protein and preserve healthy, wild-type huntingtin (wtHTT) protein.
In the multidose portion of the SELECT-HD study (n=23), participants received either every-eight-week (Q8W) intrathecal doses of 30 mg WVE-003 (n=16) or placebo (n=7), with 12 weeks of follow-up.
Key results are as follows:
<ul>
<li>WVE-003 was generally safe and well-tolerated, with no Serious Adverse Events (SAEs) reported; ventricular volume was in line with natural history.</li>
<li>Significant mHTT protein lowering was observed throughout the 28-week assessment period.
<ul>
<li>At 24 weeks (8 weeks after the last dose), mean mHTT lowering in cerebrospinal fluid (CSF) was 46% versus placebo (p=0.0007).</li>
<li>At 28 weeks (12 weeks after the last dose), mean mHTT lowering in CSF was 44% versus placebo (p=0.0002), which supports quarterly or less frequent dosing.</li>
</ul>
</li>
<li>wtHTT protein was preserved throughout the 28-week assessment period, validating allele-selective silencing. Additionally, statistically significant increases were observed in wtHTT protein versus placebo.
<ul>
<li>wtHTT protein supports the health and function of neurons and is crucial for CSF flow in the ventricles.</li>
<li>mHTT also has a detrimental effect on wtHTT at the protein level, further decreasing its function. Only selective lowering of mHTT can potentially relieve its negative impact on wtHTT protein function.</li>
</ul>
</li>
<li>Most WVE-003-treated participants had neurofilament light protein (NfL) levels that were in the range of placebo or had NfL levels that increased and returned to the range of placebo.</li>
<li>At 24 weeks (the last MRI assessment), mHTT reduction was correlated with slowing of caudate atrophy (R=-0.50; p=0.047). Caudate atrophy is an imaging biomarker predictive of clinical outcomes, including clinically meaningful worsening of Total Motor Score (TMS).</li>
<li>A slowing of decline was observed for TMS for WVE-003 versus placebo (4.25 mean difference at 24 weeks, p=not significant).</li>
</ul>
Wave expects that its current cash and cash equivalents of $181 million will be sufficient to fund operations into the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38727479/wave-life-sciences-reports-first-quarter-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">fourth quarter of 2025</a>.
Price Action: WVE shares traded down 3.07% at $5.05 at last check Tuesday.
Photo via Shutterstock

What's Going On With Wave Life Sciences Stock On Tuesday?

<ul>
<li>Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort</li>
<li>Statistically significant correlation between mHTT lowering and slowing of caudate atrophy - an imaging biomarker predictive of clinical outcomes</li>
<li>Wave to engage regulators on a clinical development path for WVE-003 that would support a potential accelerated approval, and will submit its opt-in package to program partner Takeda</li>
<li>Data provide further validation for Wave&#39;s RNA medicines platform, including PN chemistry, and pipeline; Wave remains on track to deliver 6-month dystrophin data for WVE-N531 in DMD in 3Q 2024 and RNA editing proof-of-mechanism data for WVE-006 in AATD in 2024, as well as to initiate a clinical trial for its INHBE GalNAc siRNA (WVE-007) for obesity in 1Q 2025</li>
</ul>

Wave Life Sciences Announced Results From Its Phase 1B/2A SELECT-HD Trial Of WVE-003 For Huntington's Disease, Demonstrating Mutant Huntingtin Lowering Of 46%, With Preservation Of Wild-type Huntingtin

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.4, along with a high estimate of $19.00 and a low estimate of $5.00. This current average reflects an increase of 14.82% from the previous average price target of $11.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1715778057_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive WAVE Life Sciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WAVE Life Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for WAVE Life Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into WAVE Life Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering WAVE Life Sciences: A Closer Look</h2>
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>WAVE Life Sciences: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining WAVE Life Sciences's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -3.02% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: WAVE Life Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -251.7%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -97.07%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): WAVE Life Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.37%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.2, WAVE Life Sciences faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Wells Fargo analyst Tiago Fauth initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight rating and announces Price Target of $11.

Wells Fargo Initiates Coverage On WAVE Life Sciences with Overweight Rating, Announces Price Target of $11

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $12.54 million which missed the analyst consensus estimate of $22.95 million by 45.37 percent. This is a 3.02 percent decrease over sales of $12.93 million the same period last year.

WAVE Life Sciences Q1 EPS $(0.24) Misses $(0.21) Estimate, Sales $12.54M Miss $22.95M Estimate

Wave Life Sciences receives FDA rare disease designation for its duchenne muscular dystrophy treatment

Wave Life Sciences (WVE) just unveiled an announcement. Wave Life Sciences Ltd. shareholders, at their 2024 Annual General Meeting, have approved s...

Wave Life Sciences Shareholders Approve Key Proposals at AGM

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Q32 Bio (QTTB – Research Report), Wave Life Sciences...

Analysts Are Bullish on These Healthcare Stocks: Q32 Bio (QTTB), Wave Life Sciences (WVE)

Truist Financial analyst Joon Lee maintained a Buy rating on Wave Life Sciences (WVE – Research Report) today. The company's shares closed yesterda...

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Dyne stock tumbles 31% amid drug updates, management changes

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/9/2024, According to Top Analysts

Wave Life Sciences initiated with Overweight at J.P. Morgan

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Wave Life Sciences (WVE – Research Report) on September 8 and set a price targe...

Buy Rating Affirmed for Wave Life Sciences with Promising Clinical Data and Upcoming Milestones

Mayank Mamtani, an analyst from B.Riley Financial, has initiated a new Buy rating on Wave Life Sciences (WVE). Mayank Mamtani has given his Buy rat...

Wave Life Sciences: A Buy Rating on Groundbreaking RNA Therapies and Promising Clinical Trials

Wave Life Sciences gains as B. Riley issues buy on RNS editing tech

CAPR

CPRX

CRWD

EWTX

KURA

MSCLF

PEPG

QTTB

RGNX

RHHBY

SLDB

SRPT

TRDA

VRTX

Press Releases

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

Management

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

WAVE Life Sciences

WAVE Life Sciences (WVE) Forecast

WAVE Life Sciences (NASDAQ:WVE) Stock, Quote.Headers.trade-ideas